Clinical Trial: A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas(R), Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146711) titled 'A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas(R), Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State' on Aug. 21.

Brief Summary: The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas(R), Tamsulosin hydrochloride 0,4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), in healthy adult male subjects, at steady state.

Study Start Date: March 03

Study Type: INTERVENTIONAL

Con...